TAIJI GROUP(SH:600129) Xin Jing Bao·2025-03-28 04:01Core Viewpoint - Taiji Group announced a significant downward adjustment in its 2024 profit forecast, with a projected net profit decline of 96.76% due to tax payments and decreased sales in key product categories [1][2]. Group 1: Financial Performance - The company initially forecasted a net profit of approximately 156 million yuan for 2024, representing a year-on-year decline of about 80.98% [1]. - The revised forecast estimates a net profit of around 26.65 million yuan, marking the lowest level in nearly a decade, excluding losses in 2014, 2019, and 2021 [1]. - Revenue for 2024 is expected to decrease by approximately 32.13 billion yuan, with a decline rate of 20.56%, particularly impacted by a 42.5% drop in fourth-quarter revenue [1]. Group 2: Tax Payments - Two subsidiaries of Taiji Group, Southwest Pharmaceutical Co., Ltd. and Chongqing Chinese Medicinal Materials Co., Ltd., are required to pay a total of about 100 million yuan in taxes and penalties [2]. - Southwest Pharmaceutical is responsible for 80 million yuan in income tax, while Chongqing Chinese Medicinal Materials must pay 20 million yuan in value-added tax and penalties [2]. - The tax payments will be recorded in the 2024 fiscal year and do not involve any administrative penalties [2]. Group 3: Market Performance - On March 27, Taiji Group's stock closed at 20.88 yuan per share, reflecting a decline of 1.09% [3].